Patents by Inventor Paolo Michieli

Paolo Michieli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti c-Met antibodies
    Patent number: 8637027
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: January 28, 2014
    Assignee: arGEN-X B.V.
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF
    Publication number: 20130183690
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: February 21, 2013
    Publication date: July 18, 2013
    Applicant: Metheresis Translational Research SA
    Inventors: Paolo Maria COMOGLIO, Paolo Carminati, Paolo Michieli, Cristina Basilico
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Patent number: 8404453
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: March 26, 2013
    Assignee: Metheresis Translational Research SA
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
  • C-MET ANTIBODY COMBINATIONS
    Publication number: 20120156206
    Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.
    Type: Application
    Filed: November 3, 2011
    Publication date: June 21, 2012
    Applicant: ARGEN-X B.V.
    Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Nathalie DE JONGE, Paolo MICHIELI, Cristina Basilico, Torsten Dreier
  • ANTI C-MET ANTIBODIES
    Publication number: 20120148607
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Application
    Filed: November 3, 2011
    Publication date: June 14, 2012
    Applicant: ARGEN-X B.V.
    Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Publication number: 20120115219
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: August 31, 2011
    Publication date: May 10, 2012
    Applicant: Metheresis Translational Research SA
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
  • High affinity binding site of HGFR and methods for identification of antagonists thereof
    Publication number: 20120108789
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: August 31, 2011
    Publication date: May 3, 2012
    Applicant: Metheresis Translational Research SA
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
  • HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF
    Publication number: 20090298079
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Application
    Filed: May 13, 2009
    Publication date: December 3, 2009
    Applicant: Metheresis Translational Research SA,
    Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria COMOGLIO
  • Recombinant proteins from HGF and MSP
    Patent number: 6730657
    Abstract: Recombinant proteins derived by recombination of structural domains obtained from alpha and beta subunits of HGF and/or MSP growth factors. These recombinant proteins contain domains selected from HGF and MSP, and are useful to protect cells, including differentiated cell elements of liver, kidney, and mucosa of the gastorenteral tract, from death (i.e., apoptosis) induced by chemotherapeutics.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: May 4, 2004
    Assignee: Dompe' S.p.A.
    Inventors: Enzo Medico, Paolo Michieli, Chiara Colessi, Gianfranco Caselli, Paolo Comoglio
  • Recombinant proteins derived from HGF and MSP
    Patent number: 6551991
    Abstract: Recombinant proteins deriving from recombination of structural domains deriving from the &agr; subunits of HGF and/or MSP growth factors. The recombinant proteins of the present invention have biological activity, and protect cells from death (apoptosis) induced by chemotherapeutic drugs. These molecules can conveninently be used to prevent or to treat the toxic side effects of chemotherapeutic agents used in cancer therapy.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: April 22, 2003
    Assignee: Dompe' S.p.A.
    Inventors: Enzo Medico, Paolo Michieli, Chiara Collesi, Gianfranco Caselli, Paolo Comoglio